https://campaign-image.com/zohocampaigns/313801000001230095_newsletter8.png
   

Mass-Spectrometry as an Unbiased Tool to Discover, Identify and Quantify Protein Biomarkers

   
Dear Subscriber

With 2019 already in full swing, we want to first wrap up 2018 by highlighting two DIA related news: our collaboration with PharmaFluidics and the absolute quantification with our new PQ500™ plasma kit. Then, going back to the future, we will provide you with an outlook for the upcoming conference season and software releases. 


COMBINING DIA WITH MICRO-PILLAR ARRAY COLUMNS TO INCREASE PRECISION AND SENSITIVITY 

Data-independent acquisition (DIA) has been introduced as a novel data acquisition strategy to combine the high-throughput advantages of data-dependent acquisition (DDA) with the high reproducibility of a targeted analysis such as parallel reaction monitoring (PRM). To fully benefit from the technological advantages of DIA, a maximum number of separated peaks is required from liquid chromatography, referred to as peak capacity. In normal packed chromatography columns, peak capacity is limited by the maximum length of the column and the maximum pressure that can be applied to the system. 

 More importantly, peak capacity flattens despite increasing gradient lengths, usually around 3-4 hours. In order to push the detection and quantification limits, Biognosys teamed up with PharmaFluidics and applied their micro-pillar array columns (µPAC™) in a DIA experiment using HeLa cell digest. By using µPAC, Biognosys was able to increase the overall peak capacity at any gradient length. In addition, the peak capacity scaled with increasing gradient length. This enabled Biognosys to detect and quantify on average more than 9’000 proteins per run at a gradient length of 6 hours, which represents the current highest efficiency. If you are interested in reading the complete tech note or viewing the webinar recording, please follow the links below.



UNBIASED AND ABSOLUTE QUANTIFICATION OF MORE THAN 500 PLASMA PROTEINS IN PANCREATIC CANCER

Recent studies have demonstrated the value of quantifying circulating proteins for early disease detection, prediction of therapeutic response, and treatment monitoring. Although the utility is clear, standardization of measurement methods for a large number of proteins from plasma remains challenging. In one of our most recent studies, we investigated plasma proteins using DIA mass spectrometry in samples from normal and pancreatic cancer subjects. The data was analyzed and absolutely quantified using Biognosys’ PQ500™ reference panel; constructed of 800 stable-isotope standard (SIS) peptides spanning more than 500 proteins. With our approach, we could effectively identify dysregulated proteins that are known biomarkers for pancreatic cancer. If you would like to know more about our biomarker discovery approach, please contact us at services@biognosys.com or meet us at one of the upcoming conferences.


SPECTRODIVE™ 9.0 AND QUIC™ 3.0 TO BE LAUNCHED AT EUPA AND ABRF

Targeted proteomics is a powerful, unbiased analysis methodology that combines the precision quantification known from biological methods like ELISA with high multiplexing capabilities. SpectroDive is Biognosys' data analysis software for targeted proteomics, and we are excited to unveil our new SpectroDive 9.0 at the upcoming EUPA conference. Join us in Potsdam (Berlin) to explore its new features. Are you more concerned about the performance of your mass spectrometry instrumentation? QuiC is Biognosys' performance monitoring and quality control software that minimizes instrument downtime and troubleshooting requirements through real-time monitoring of a multitude of critical performance parameters. For 2019, we also gave QuiC a significant upgrade, which will be presented at the upcoming ABRF conference. Join us in San Antonio, TX to learn more about QuiC 3.0.



MEET OUR TEAM AT THE FOLLOWING CONFERENCES AND EVENTS


ESMO Targeted Anticancer Therapies

February 25-28, 2019, Paris, France


ASCO-SITC Clinical Immuno-Oncology Symposium

February 28-March 2, 2019, San Francisco, CA, USA

 

Keystone Symposium on Phenotypic Drug Discovery

March 3-7, 2019, Breckenridge, CO


ABRF

March 23-26, 2019, San Antonio, TX, USA


EUPA

Proteomics Forum, March 24-28, 2019, Potsdam, Germany


AACR Annual Meeting

March 29-April 2, 2019, Atlanta, GA, USA


MSACL - Mass Spectrometry: Applications to the Clinical Lab

March 31-April 4, 2019, Palm Springs, CA, USA


Keystone Symposium on Proteomics and its Application to 

Translational and Precision Medicine

April 7-11, 2019, Stockholm, Sweden


ASGCT Annual Meeting

April 29-May 2, 2019, Washington DC, USA


SPS Annual Swiss Proteomics Meeting

May 23-24, 2019, Montreux, Switzerland 


ASMS 2019 Annual Conference

June 2-6, Atlanta, GA, USA



Best regards,

The Biognosys Team

   
https://campaign-image.com/zohocampaigns/313801000001230095_5_signature.png
   


Can't read or view images? View in Browser

Want to edit your profile? Update Profile

Not interested? Unsubscribe

No more? Opt Out from Organization


   
   
Twitter
LinkedIn
YouTube
RSS